Redian新闻
>
魏于全居然还在川大
avatar
魏于全居然还在川大# Biology - 生物学
c*6
1
Available positions:
We are still seeking outstanding candidates who hold an advanced degree (
Ph.D. or M.D.) and a strong record of research or clinical achievements to
fill 30 faculty positions at the associate/full professor level.
Applications are especially welcomed from candidates who have demonstrated
the potential for developing an internationally recognized research or
clinical program in the field of, but not limited to, structural biology,
epigenetics, synthetic biology, genomics, immunology, molecular cell biology
,developmental biology,biopharmaceuticals R&D, gene & cell therapy,
monoclonal antibody and vaccine, stem cell/tissue engineering, computer-
aided drug design, chemical biology, and clinical medicine, especial in the
development of novel therapeutic approaches. Both Chinese and non-Chinese
nationals are encouraged to apply. All positions will be filled on the “
first come, first served” basis.
Application:
Those offered a faculty position will enjoy an outstanding competitive
start-up package, excellent space, satisfied core facilities housing subsidy
. A highly competitive salary will be commensurate with qualifications and
experience. Applicants should send their CV and a brief description (300-
500 words) of research interests to: Prof. Yu-quan Wei, E-mail: [email protected]/* */
sina.com.
avatar
Z*5
2
他在那里搞得风生水起呀,对下面的年青人也非常提携。
avatar
s*y
3
Nature集团跟华西联合办了一份杂志Signal Transduction and Targeted Therapy,
魏于全是主编之一。他还是川大副校长吧?
Prof. Yu-Quan Wei, State Key Laboratory of Biotherapy/Collaborative
Innovation Center of Biotherapy, West China Hospital, Sichuan University,
China
Yu-quan Wei, Ph.D., Professor and Director of National/State Key Laboratory
of Biotherapy and Clinical Cancer Center, West China Hospital, West China
Medical School, Sichuan University, Chengdu. He was educated at West China
University of Medical Sciences for a bachelor's degree in Medicine and a
Master's Degree in Medicine, and educated at Kyoto University in Japan for
Doctoral Degree. His major research interests include: targeted therapy,
signal transduction, gene and cell therapy, and cancer vaccines. He has
published more than 300 papers in international journals including Nat Med,
Nat Commun, PNAS, Blood, Cancer Res, Clinic Cancer Res, J Immunol, and J
Biol Chem, etc. He was selected as an academician of Chinese Academy of
Sciences in 2003. He is now the vice president of Sichuan University,
President of China Medicinal Biotech Association, Vice President of Chinese
Association of Medicine. He has served as an associate editor of Human Gene
Therapy and Editorial Board Member of several International Journals.
相关阅读
logo
联系我们隐私协议©2024 redian.news
Redian新闻
Redian.news刊载任何文章,不代表同意其说法或描述,仅为提供更多信息,也不构成任何建议。文章信息的合法性及真实性由其作者负责,与Redian.news及其运营公司无关。欢迎投稿,如发现稿件侵权,或作者不愿在本网发表文章,请版权拥有者通知本网处理。